09:13 AM EST - Oncolytics Biotech Inc : Today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San FranciscoJanuary 23-25, 2025. Oncolytics Biotech Inc
shares T.ONC are trading off $0.05 at $1.13.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=7548720914543258
